0001437749-22-005699.txt : 20220309 0001437749-22-005699.hdr.sgml : 20220309 20220309164037 ACCESSION NUMBER: 0001437749-22-005699 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220309 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220309 DATE AS OF CHANGE: 20220309 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SAFEGUARD SCIENTIFICS INC CENTRAL INDEX KEY: 0000086115 STANDARD INDUSTRIAL CLASSIFICATION: INVESTORS, NEC [6799] IRS NUMBER: 231609753 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-05620 FILM NUMBER: 22725914 BUSINESS ADDRESS: STREET 1: 150 NORTH RADNOR-CHESTER ROAD STREET 2: SUITE F-200 CITY: RADNOR STATE: PA ZIP: 19087 BUSINESS PHONE: 610 293 0600 MAIL ADDRESS: STREET 1: 150 NORTH RADNOR-CHESTER ROAD STREET 2: SUITE F-200 CITY: RADNOR STATE: PA ZIP: 19087 FORMER COMPANY: FORMER CONFORMED NAME: SAFEGUARD INDUSTRIES INC DATE OF NAME CHANGE: 19810525 FORMER COMPANY: FORMER CONFORMED NAME: SAFEGUARD CORP DATE OF NAME CHANGE: 19690521 8-K 1 sfe20220309_8k.htm FORM 8-K sfe20220309_8k.htm
false 0000086115 0000086115 2022-03-09 2022-03-09
 
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): March 9, 2022
 
Safeguard Scientifics, Inc.
(Exact Name of registrant as Specified in Charter)
 
 
Pennsylvania
1-5620
23-1609753
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer ID No.)
 
150 N. Radnor Chester Rd., Ste F-200
Radnor, PA
19087
(Address of Principal Executive Offices)
(Zip Code)
 
Registrant’s telephone number, including area code: 610-293-0600
 
Not applicable 
(Former Name or Former Address if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock ($.10 par value)
SFE
New York Stock Exchange
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
 
Item 2.02.          Results of Operations and Financial Condition.
 
On March 9, 2022 Safeguard Scientifics, Inc. (the “Company”) issued a press release setting forth the Company’s financial information for the three months and year ended December 31, 2021. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is hereby incorporated by reference.
 
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
 
Item 9.01.         Financial Statements and Exhibits.
 
(d)
Exhibits.
 
99.1
104
Cover Page Interactive Data File (formatted as Inline XBRL).
 
2
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Safeguard Scientifics, Inc.
  
       
       
Date: March 9, 2022
By:
/s/ G. Matthew Barnard
  
 
Name:        G. Matthew Barnard
  
 
Title:          General Counsel
  
     
 
 
 
3
 
 EX-99.1 2 ex_345106.htm EXHIBIT 99.1 ex_345106.htm
 

Exhibit 99.1

logo.jpg 

 

SAFEGUARD SCIENTIFICS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2021 FINANCIAL RESULTS

 

Cash proceeds of $60.8 million from exits during 2021

Repurchases of 4.5 million common shares during 2021

Initiates evaluation of strategic options

 

 

Conference call and webcast on March 9, 2022 at 5 p.m. ET

 

 

Radnor, PA, March 9, 2022 — Safeguard Scientifics, Inc. (NYSE:SFE) (“Safeguard” or the “Company”) today announced financial results for the full year and three months ended December 31, 2021.

 

2021 HIGHLIGHTS

 

 

●

Capital Return
 

o

On October 7, 2021, Safeguard completed a modified Dutch auction self-tender that resulted in the repurchase of 4.3 million shares of its common stock at a cost of $39.0 million, or $9.06 per share, including transaction costs.
 

o

Safeguard also repurchased 236,159 shares on the open market for $1.6 million, or $6.94 per share during the second and third quarters of 2021.

 

 

●

Exits & Deployments
 

o

During the fourth quarter, Safeguard received $2 million of additional proceeds resulting from the resolution of certain contingent consideration terms under the 2018 sale of AdvantEdge Healthcare Solutions.
 

o

During the third quarter, Flashtalking was acquired by Mediaocean resulting in Safeguard receiving $44.8 million of cash proceeds upon the closing. As a result of this exit and the collection of $0.2 million of escrow amounts in the fourth quarter, Safeguard reported a gain on Flashtalking of $32.5 million for the year ended December 31, 2021.
 

o

During the first quarter, Zipnosis was acquired by Bright Health Group (BHG), a national integrated healthcare company. Safeguard received $3.5 million of cash proceeds and $15.3 million of preferred equity in BHG resulting in a gain of $17.3 million (see “Safeguard Company Performance” below for subsequent developments).
 

o

Safeguard also received $10.1 million of cash proceeds, including escrow amounts resolved to-date, from the exits of WebLinc, Velano Vascular and T-REX Group in separate transactions.
 

o

Safeguard’s 2021 deployments were limited to $1.7 million to Aktana in the third quarter and $1.0 million to Trice Medical in the first quarter. The aggregate of $2.7 million of deployments was less than the $5 million to $7 million expected at the beginning of the year primarily due to certain expected deployments being postponed until 2022.
 

o

Subsequent to year-end, Safeguard funded a $2 million convertible loan to Prognos Health, with other existing investors also participating.

 

 

●

Safeguard Company Performance
 

o

BHG completed an initial public offering during the second quarter resulting in the conversion of Safeguard’s BHG preferred stock into 1.3 million shares of common stock (subject to lock-up) and an unrealized gain of $7.4 million for the quarter. During the third and fourth quarters, Safeguard’s shares of Bright Health common stock experienced unrealized declines in fair value of $11.9 million and $6.3 million, respectively. Based on the closing price as of December 31, 2021, the fair value of Safeguard’s Bright Health common stock was $4.5 million.

 

 

  

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved.  
1 of 8
 
 
logo.jpg

 

 

o

During 2021, two Safeguard companies raised growth equity capital. Syapse raised $68 million in the first quarter from new investors and Trice raised capital in the third quarter in a financing led by a strategic investor, resulting in aggregate unrealized dilution gains of $9.3 million for both transactions.
 

o

The aggregate trailing twelve-month revenues ending September 30, 2021 for Safeguard’s ten companies, which excludes Flashtalking (exited in August 2021), Bright Health and Other Ownership Interests, was $246 million, down 7.1% from the comparable prior period.

 

 

●

Financial Results
 

o

Cash, cash equivalents and restricted cash totaled $24.8 million at December 31, 2021.
 

o

The carrying value of the Company’s ownership interests totaled $26.5 million at December 31, 2021, which includes the Bright Health common stock noted above. The total cost of Safeguard’s ownership interests was $155.8 million.
 

o

Net loss for the three months ended December 31, 2021 was $8.6 million, or $0.51 per share, compared with a net loss of $7.4 million, or $0.35 per share, for the same period in 2020.
 

o

Net income for the year ended December 31, 2021 was $27.0 million, or $1.36 per share, as compared with a net loss of $37.6 million, or $1.81 per share, for the year ended December 31, 2020.

 

 

●

Operating Costs
 

o

Safeguard continued to reduce its operating costs throughout 2021. General and administrative expenses totaled $1.1 million for the fourth quarter of 2021, as compared to $1.6 million for the comparable period of 2020. General and administrative expenses for the year ended December 31, 2021 were $7.2 million as compared to $9.5 million for the year ended December 31, 2020.
 

o

Safeguard also continued to lower its corporate expenses,1 which totaled $0.8 million for the fourth quarter of 2021, as compared to $1.2 million for the comparable period of 2020, a 33% decline. Corporate expenses totaled $3.9 million for the year ended December 31, 2021, as compared to $5.2 million for the year ended December 31, 2020, a 25% annual decline.

 

 

●

Outlook
 

o

Safeguard expects follow-on deployments for its remaining ownership interests for 2022 of $5 million to $9 million. 
 

o

Safeguard will continue to closely manage corporate expenses in 2022 and has established a target of $3.5 million to $4.0 million for the year, exclusive of transaction related expenses if any.   
 

o

Safeguard has engaged Houlihan Lokey as its financial advisor to evaluate strategic alternatives for the Company.

 

 

“We made significant progress in 2021 maximizing the value of our portfolio company interests, driving exits, and returning cash to our shareholders. These efforts resulted in the successful self-tender transaction in Q3 2021 where we repurchased approximately $40 million of our stock or 22% of our outstanding shares. We remain excited about the portfolio and executing our strategy in 2022. We also recognize that there might be other avenues to further maximize shareholder value. To that end, we engaged Houlihan Lokey as our financial advisor to help us evaluate strategic transactions that may further maximize value to our shareholders,” said Eric C. Salzman, Chief Executive Officer.

 

 

 

1 Corporate expenses are general and administrative expenses excluding depreciation, severance, stock-based compensation and other non-recurring items.  See full reconciliation in the financial section of this statement.

  

 

 

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved.  
2 of 8
 

 

logo.jpg

 

OWNERSHIP INTERESTS AT DECEMBER 31, 2021

 

Companies

Category

Acquisition Year

  

Primary Ownership%

    

Fully Diluted Ownership%

**

    

Carrying

Value

(in millions)

    

Cost

(in millions)

  
                                     

Initial Revenue Stage: Up to $1 million

 

None

                                    

Revenue of $1 million to $5 million

 

Moxe Health Corporation

Healthcare

2016

     27.6 %     25.4 %   $ 3.7     $ 7.5  

Revenue of $5 million to $10 million

 

Lumesis, Inc.

Financial Services

2012

     43.2 %     43.3 %     1.6       5.6  

Revenue of $10 million to $20 million

 

Clutch Holdings, Inc.

Digital Media

2013

     41.7 %     33.0 %     4.4       16.9  

InfoBionic, Inc.

Healthcare

2014

     25.2 %     22.1 %     -       22.0  

meQuilibrium

Healthcare

2015

     31.9 %     22.9 %     2.2       14.0  

Syapse, Inc.

Healthcare

2014

     11.1 %     8.9 %     5.4       25.0  

Trice Medical, Inc.

Healthcare

2014

     12.6 %     9.0 %     1.2       11.8  

Revenue of $20 million to $50 million

 

Aktana, Inc.

Healthcare

2016

     13.4 %     11.4 %     -       15.9  

Prognos Health, Inc.

Healthcare

2011

     28.5 %     24.6 %     2.6       12.6  

Revenue greater than $50 million

 

MediaMath, Inc.

Digital Media

2009

     13.2 %     10.1 %     -       15.5  

Other Ownership Interests

  

Bright Health Group

Healthcare

2021

                     4.5       -  

All others

Various

                     0.9       9.0  
               

TOTAL:

     $ 26.5     $ 155.8  

 

 

** Based on information provided by each respective company. Assumes the conversion or exercise of all currently outstanding securities including the issuance of all shares available under authorized employee equity programs. Does not reflect liquidation preferences, priority payments, proceeds from option and/or warrant exercises or other company-specific transaction-related obligations in a liquidation or exit transaction.

 

 

  

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved.  
3 of 8
 

 

logo.jpg

 

CONFERENCE CALL AND WEBCAST DETAILS

 

Please call 10-15 minutes prior to the call to register.

 

Date: March 9, 2022

 

Time: 5 p.m. ET

 

Webcast: https://events.q4inc.com/attendee/352425345

 

Live Number: 844-200-6205

 

Access Code: 544056

 

Speakers: Chief Executive Officer, Eric C. Salzman; and Senior Vice President and Chief Financial Officer, Mark A. Herndon

 

Format: Discussion of the full year and fourth quarter’s financial results followed by Q&A

 

The replay will be available by telephone (866-813-9403; access code 185142) through March 16, 2022. The webcast replay will be available for 90 days at Safeguard.com’s investor relations site under “Past events”. For more information please contact IR@safeguard.com. 

 

 

  

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved.  
4 of 8
 

 

logo.jpg

 

About Safeguard Scientifics

Historically, Safeguard Scientifics has provided capital and relevant expertise to fuel the growth of technology-driven businesses. Safeguard has a distinguished track record of fostering innovation and building market leaders that spans more than six decades. Safeguard is currently pursuing a focused strategy to value-maximize and monetize its ownership interests over a multi-year time frame to drive shareholder value. For more information, please visit www.safeguard.com.

 

Forward-Looking Statements

Except for the historical information and discussions contained herein, statements contained in this release may constitute “forward-looking statements.” Our forward-looking statements are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding Safeguard’s ability to maximize the value of monetization opportunities of its ownership interests and drive total shareholder returns. Safeguard’s initiatives taken or contemplated to enhance and unlock value for all of its shareholders, Safeguard’s efforts to execute on and implement its strategy to streamline its organizational structure, reduce its operating costs, pursue monetization opportunities for ownership interests and maximize the return of value to its shareholders, Safeguard’s ability to create, unlock, enhance and maximize shareholder value, the effect of Safeguard’s management succession plan on driving increased organizational effectiveness and efficiencies, the ability of the management team to execute Safeguard’s strategy, the availability of, the timing of, and the proceeds that may ultimately be derived from the monetization of ownership interests, Safeguard’s projections regarding the reduction in its ongoing operating expenses, Safeguard’s projections regarding annualized operating expenses and expected severance expenses, monetization opportunities for ownership interests, and the amount of net proceeds from the monetization of ownership interests that will enable the return of value to Safeguard shareholders after satisfying working capital needs and the timing of such return of value. Such forward-looking statements are not guarantees of future operational or financial performance and are based on current expectations that involve a number of uncertainties, risks and assumptions that are difficult to predict. Therefore, actual outcomes and/or results may differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties that could cause actual results to differ materially include, among others, our ability to make good decisions about the monetization of our ownership interests for maximum value or at all and the return of value to our shareholders, our ability to successfully execute on our strategy to streamline our organizational structure and align our cost structure to increase shareholder value, whether our strategy will better position us to focus our resources on the highest-return opportunities and deliver enhanced shareholder value, the ongoing support of our existing ownership interests, the fact that our companies may vary from period to period, challenges to achieving liquidity from our ownership interests, fluctuations in the market prices of our publicly traded holdings, if any, competition, our inability to obtain maximum value for our ownership interests, our ability to attract and retain qualified employees, market valuations in sectors in which our ownership interests operate, our inability to control our ownership interests, our need to manage our assets to avoid registration under the Investment Company Act of 1940, risks, disruption, costs and uncertainty caused by or related to the actions of activist shareholders, including that if individuals are elected to our Board with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create value for our shareholders and perceived uncertainties as to our future direction as a result of potential changes to the composition of our Board may lead to the perception of a change in the direction of our business, instability or a lack of continuity that may adversely affect our business, and risks associated with our ownership interests, including the fact that most of our ownership interests have a limited operating history and a history of operating losses, face intense competition and may never be profitable, the effect of economic conditions in the business sectors in which our companies operate, and other uncertainties described in our filings with the Securities and Exchange Commission. Many of these factors are beyond our ability to predict or control. As a result of these and other factors, the Company’s past operational and financial performance should not be relied on as an indication of future performance. Further information on the above risk factors and other potential factors that could affect our future business, operating results and financial condition is included in our Annual Report on Form 10-K for the year ended December 31, 2021 and other periodic filings with the Securities and Exchange Commission, including risks under the heading “Risk Factors.” The Company does not assume any obligation to update any forward-looking statements or other information contained in this press release.

 

###

 

SAFEGUARD CONTACT:

Mark Herndon

Chief Financial Officer

(610) 975-4913

mherndon@safeguard.com

 

 

  

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved.  
5 of 8
 

 

logo.jpg

 

Safeguard Scientifics, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

 

   

December 31, 2021

    

December 31, 2020

  

Assets

                

Cash, cash equivalents and restricted cash

   $ 24,764     $ 15,601  

Ownership interests

     4,549       —  

Other current assets

     965       462  

Total current assets

     30,278       16,063  

Ownership interests in and advances

     21,972       50,398  

Other assets

     1,778       2,574  

Total Assets

   $ 54,028     $ 69,035  
                 

Liabilities and Equity

                

Other current liabilities

   $ 1,734     $ 3,470  

Total current liabilities

     1,734       3,470  

Lease liability - non-current

     1,678       2,053  

Other long-term liabilities

     50       637  

Total equity

     50,566       62,875  

Total Liabilities and Equity

   $ 54,028     $ 69,035  

 

 

  

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved.  
6 of 8
 

 

logo.jpg

 

Safeguard Scientifics, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

 

   

Three Months Ended

    

Twelve Months Ended

  
   

December 31,

    

December 31,

  
   

2021

    

2020

    

2021

    

2020

  

Operating expenses

   $ 1,135     $ 1,631     $ 7,153     $ 9,466  

Operating loss

     (1,135

)

     (1,631

)

     (7,153

)

     (9,466

)

Other income (loss), net

     (5,992

)

     (663

)

     22,035       (7,708

)

Interest, net

     79       52       276       261  

Equity income (loss), net

     (1,586

)

     (5,111

)

     11,846       (20,702

)

Net income (loss) before income taxes

     (8,634

)

     (7,353

)

     27,004       (37,615

)

Income tax benefit (expense)

     —       —       —       —  

Net income (loss)

   $ (8,634

)

   $ (7,353

)

   $ 27,004     $ (37,615

)

Net income (loss) per share:

                                

Basic

   $ (0.51

)

   $ (0.35

)

   $ 1.36     $ (1.81

)

Diluted

   $ (0.51

)

   $ (0.35

)

   $ 1.36     $ (1.81

)

Weighted average shares used in computing income (loss) per share:

                                

Basic

     16,798       20,829       19,827       20,751  

Diluted

     16,798       20,829       19,827       20,751  

 

 

  

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved.  
7 of 8
 

 

logo.jpg

 

Safeguard Scientifics, Inc.

Financial Data

(in thousands)

 

Additional Financial Information

 

Non-GAAP Measures

 

In discussing financial results and guidance, the Company refers to the measure "corporate expenses" which is not in accordance with Generally Accepted Accounting Principles (GAAP). We use this non-GAAP financial measure internally to make operating and strategic decisions, including evaluating our overall performance and as a factor in determining compensation for certain employees. We have defined corporate expenses as general and administrative costs excluding stock based compensation, severance costs, and non-recurring items and other.  Non-recurring items and other includes accruals related to the Company's LTIP plan that will not be paid until reaching a specified threshold within that plan. We believe presenting this non-GAAP financial measure provides additional information to facilitate comparison of our historical operating costs and their trends, and provides additional transparency on how we evaluate our cost structure. We also believe presenting this measure allows investors to view our performance using the same measure that we use in evaluating our performance and trends.

 

Corporate expenses reconciliation:

 

   

Three Months Ended

    

Twelve Months Ended

  
   

December 31,

    

December 31,

  
   

2021

    

2020

    

2021

    

2020

  

Corporate expenses

   $ 825     $ 1,219     $ 3,865     $ 5,216  

Stock based compensation

     310       (14

)

     1,779       965  

Severance costs

     —       147       774       2,020  

Non-recurring items and other

     —       279       735       1,265  

General and administrative expenses

   $ 1,135     $ 1,631     $ 7,153     $ 9,466  

 

 

  

www.safeguard.com © 2022 Safeguard Scientifics, Inc. All rights reserved.  

 

8 of 8
 EX-101.SCH 3 sfe-20220309.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 sfe-20220309_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 sfe-20220309_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 sfe-20220309_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 logo.jpg begin 644 logo.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document And Entity Information
Mar. 09, 2022
Document Information [Line Items]  
Entity, Registrant Name Safeguard Scientifics, Inc.
Document, Type 8-K
Document, Period End Date Mar. 09, 2022
Entity, Incorporation, State or Country Code PA
Entity, File Number 1-5620
Entity, Tax Identification Number 23-1609753
Entity, Address, Address Line One 150 N. Radnor Chester Rd., Ste F-200
Entity, Address, City or Town Radnor
Entity, Address, State or Province PA
Entity, Address, Postal Zip Code 19087
City Area Code 610
Local Phone Number 293-0600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol SFE
Security Exchange Name NYSE
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0000086115
XML 9 sfe20220309_8k_htm.xml IDEA: XBRL DOCUMENT 0000086115 2022-03-09 2022-03-09 false 0000086115 8-K 2022-03-09 Safeguard Scientifics, Inc. PA 1-5620 23-1609753 150 N. Radnor Chester Rd., Ste F-200 Radnor PA 19087 610 293-0600 false false false false Common Stock SFE NYSE false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 122 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.sfe.com/20220309/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports sfe20220309_8k.htm ex_345106.htm sfe-20220309.xsd sfe-20220309_def.xml sfe-20220309_lab.xml sfe-20220309_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sfe20220309_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "sfe-20220309_def.xml" ] }, "inline": { "local": [ "sfe20220309_8k.htm" ] }, "labelLink": { "local": [ "sfe-20220309_lab.xml" ] }, "presentationLink": { "local": [ "sfe-20220309_pre.xml" ] }, "schema": { "local": [ "sfe-20220309.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 0, "memberStandard": 0, "nsprefix": "sfe", "nsuri": "http://www.sfe.com/20220309", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sfe20220309_8k.htm", "contextRef": "d20228K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.sfe.com/20220309/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sfe20220309_8k.htm", "contextRef": "d20228K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220309/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220309/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220309/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220309/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220309/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220309/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220309/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220309/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220309/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220309/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220309/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220309/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220309/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220309/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220309/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220309/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220309/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220309/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220309/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220309/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220309/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220309/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220309/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220309/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20220309/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001437749-22-005699-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-22-005699-xbrl.zip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end